Myeloproliferative Neoplasma (MPNs) Update – Spring 2020
FDA Approval of Fedratinib – Dr. Mesa answers your questions
MPN 2019 Summer Update – Dr Mesa and Dr Scherber
“Cancer is a Thief” – Ruben Mesa, M.D., FACP
Ruben Mesa MD and Robyn Scherber MD Mays Cancer Center/ UT Health San Antonio MD Anderson Diagnosis, Symptoms, Treatments for the newly diagnosed patient.
Answering Common Patient Questions on Myeloproliferative Neoplasms – Mayo Clinic
Ruben Mesa, M.D., Chair of Hematology and Oncology at Mayo Clinic in Arizona, discusses common patient questions regarding myeloproliferative neoplasms with John Camoriano, M.D., medical oncology consultant at Mayo Clinic.
Top 10 Tips for Battling the Fatigue Associated with Myeloproliferative Neoplasms – Mayo Clinic
Ruben Mesa, M.D., hematologist and Deputy Director of the Mayo Clinic Cancer Center in Arizona, provides his top ten recommendations for battling the fatigue associated with a diagnosis of myeloproliferative neoplasm.
Drivers or Passengers? Genetics of MDS and MDS/MPN
Diagnosis of MDS or MDS/MPN must begin with morphology (analysis of the form and structure of patient blood or bone marrow cells). When used alone, today’s advanced techniques to study genes and chromosomes don’t give enough information to find out what type of MDS or MDS/MPN a patient has.